Related Experiment Video
Updated: May 6, 2026
Combining QD-FRET and Microfluidics to Monitor DNA Nanocomplex Self-Assembly in Real-Time
Published on: August 26, 2009
Nicking endonuclease-propelled DNA nanoassemblies enable cross-validated trimodal biosensing with ultrahigh
Xu Li1, Yashu Wei2, Peiyuan Li1
1Key Laboratory of Optic-electric Chemo/Biosensing and Molecular Recognition(Guangxi Minzu University), Education Department of Guangxi Zhuang Autonomous Region, School of Chemistry and Chemical Engineering, Guangxi Minzu University, Nanning, 530006, China.
This study introduces a novel trimodal biosensing platform using nicking endonuclease and rolling circle amplification for enhanced reliability. It integrates electrochemical, colorimetric, and photothermal detection for accurate biomarker analysis.
Area of Science:
- Biomolecular Engineering
- Nanomaterials Science
- Analytical Chemistry
Background:
- Current biosensors suffer from reliability issues due to single-signal outputs, leading to false positives and poor anti-interference.
- Limitations in environmental adaptability and complex matrix applicability hinder the performance of existing biosensing platforms.
Purpose of the Study:
- To develop a highly reliable and adaptable trimodal biosensing platform overcoming single-signal output limitations.
- To integrate electrochemical (EC), colorimetric (CL), and photothermal (PTM) detection modes for robust biomarker quantification.
- To provide a generalizable framework for next-generation biosensing with multi-mode cross-validation.
Main Methods:
- Utilized nicking endonuclease-propelled rolling circle amplification (RCA) for signal amplification and DNA nanoassembly.
- Engineered a novel AuNPs/Zr-MOF/GDY nanocomposite for improved electron transfer and surface area.
- Implemented DNAzyme walker-driven cascade reactions and triple-mode output for enhanced sensitivity and validation.
Main Results:
- Achieved exceptional CD17 detection with ultra-low limits of detection: 31.7 aM (EC), 11.2 fM (CL), and 10.3 fM (PTM).
- Demonstrated a wide linear detection range from 0.0001 to 100,000 pM for CD17.
- Validated successful human serum analysis with 97.7-106.3% recovery, confirming clinical utility for thalassemia screening.
Conclusions:
- The developed trimodal biosensing platform offers fundamental solutions to reliability challenges in biosensing.
- Multi-mode cross-validation, enzyme-driven amplification, and robust nanoarchitectures enable adaptable biomarker detection.
- This work presents a generalizable framework for designing next-generation biosensors with improved performance and adaptability.
